PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Verdict

Headline takes no side. We score PMVP +0.80 — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · PMVP

+0.80strongly bullish

−1 bearish0bullish +1

More positive than 87% of ticker scores this week